Skip to main content

Iterum Therapeutics to Present Data at IDWeek 2025

Written by Customer Service on . Posted in Public Companies.

DUBLIN and CHICAGO, Oct. 14, 2025 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that two posters will be presented at the Infectious Disease Society of America’s IDWeek 2025 conference taking place in Atlanta, GA from October 19-22, 2025.

The Company will also be conducting a Learning Lounge at IDWeek 2025 on Tuesday, October 21, 2025, 1:15 pm EST. The title of the presentation is ‘An Overview of Urinary Tract Infection in Adult Women: Focus on Oral Sulopenem.’ Presenters: Steven I. Aronin, M.D. and Michael Dunne, M.D.

Data to be presented at IDWeek 2025 include:

Presentation Title: Risk factors for treatment failure in patients with uncomplicated urinary tract infection
Poster #: P784
Presenter: Steven I. Aronin, MD
Time/Location: Monday, October 20, 12:15 p.m. – 1:30 p.m., Poster Hall B4-5

Presentation Title: In vitro activity of sulopenem and comparator agents against U.S. Enterobacterales clinical isolates, SENTRY antimicrobial surveillance program, 2023            
Poster #: P1208
Presenter: Steven I. Aronin, MD
Time/Location: Tuesday, October 21, 12:15 p.m. – 1:30 p.m., Poster Hall B4-5

These Posters will be made available on the Company’s website on the “Publications: Posters & Presentations” page under the “Our Science” tab once the conference ends.

About ORLYNVAH™

ORLYNVAH™ is a novel oral penem antibiotic for the treatment of uncomplicated urinary tract infections (uUTIs). ORLYNVAH™ possesses potent activity against species of Enterobacterales including those that encode extended spectrum beta-lactamases (ESBL) or AmpC-type ß-lactamases that confer resistance to third generation cephalosporins.

About Iterum Therapeutics plc

Iterum Therapeutics plc is focused on delivering differentiated anti-infectives aimed at combatting the global crisis of multi-drug-resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum is advancing the development of its first compound, sulopenem, a novel penem anti-infective compound, with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum has received U.S. Food and Drug Administration approval for ORLYNVAH™ (oral sulopenem) for the treatment of uUTIs caused by Escherichia coli, Klebsiella pneumoniae or Proteus mirabilis in adult women with limited or no alternative oral antibacterial treatment options, and ORLYNVAH™ is commercially available in the United States. Iterum has also been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. For more information, please visit www.iterumtx.com.

Investor Contact:
Judy Matthews
Chief Financial Officer
872-225-6077
IR@iterumtx.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.